Q-omics provides the consensus-scored IGLJ1 profile across patient tissues and cancer cell-line models. IGLJ1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLJ1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, IGLJ1 RNA expression shows 7,746 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where IGLJ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLJ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLJ1 survival associations across molecular data types. IGLJ1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLJ1 RNA expression–survival associations across cancer types. High IGLJ1 expression shows unfavorable associations in KICH, but favorable associations in HNSC, SKCM, BLCA, BRCA and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLJ1 RNA expression.
This table summarizes IGLJ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLJ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLJ1 shows lower tumor expression in COAD, READ and BRCA and higher tumor expression in KIRC, LUAD and BLCA. The COAD box plot shows higher IGLJ1 RNA expression in normal versus tumor tissue (log2 FC = −1.745, t-test p < 0.001).
This table shows molecular features associated with IGLJ1 in patient tissues and cancer cell lines. In patient samples, IGLJ1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
